Cancer risk in Korean patients with gout
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Using a nationwide cohort, we investigated the cancer risk in Korean patients with gout. Methods: Data were obtained from the Korean National Health Insurance Service Database. Patients with gout were defined as those aged ≥ 20 years who were diagnosed with gout and received anti-gout medication (allopurinol, colchicine, and benzbromarone) between 2008 and 2010. Patients with nail disorders were randomly assigned to a control group (1:1 ratio) after frequency matching for age and sex. Cancer incidence was then investigated between 2012 and 2018. Cox proportional hazard regression analysis was used to investigate the association between gout and cancer after adjusting for concomitant diseases. Results: This study included 179,930 patients with gout and an equal number of matched controls. The incidence of overall cancer was higher in patients with gout than in controls (incidence rate ratio, 1.08). Cox proportional hazards regression analysis showed that gout was associated with a hazard ratio of 1.053 (95% confidence interval ,1.031 to 1.077) after adjusting for concomitant diseases. Conclusions: Gout was associated with a significantly high risk of cancer, especially esophageal, stomach, colon, liver, pancreatic, lung, ovarian, renal, and bladder cancers.
Abstract
Background/Aims: Using a nationwide cohort, we investigated the cancer risk in Korean patients with gout. Methods: Data were obtained from the Korean National Health Insurance Service Database. Patients with gout were defined as those aged ≥ 20 years who were diagnosed with gout and received anti-gout medication (allopurinol, colchicine, and benzbromarone) between 2008 and 2010. Patients with nail disorders were randomly assigned to a control group (1:1 ratio) after frequency matching for age and sex. Cancer incidence was then investigated between 2012 and 2018. Cox proportional hazard regression analysis was used to investigate the association between gout and cancer after adjusting for concomitant diseases. Results: This study included 179,930 patients with gout and an equal number of matched controls. The incidence of overall cancer was higher in patients with gout than in controls (incidence rate ratio, 1.08). Cox proportional hazards regression analysis showed that gout was associated with a hazard ratio of 1.053 (95% confidence interval ,1.031 to 1.077) after adjusting for concomitant diseases. Conclusions: Gout was associated with a significantly high risk of cancer, especially esophageal, stomach, colon, liver, pancreatic, lung, ovarian, renal, and bladder cancers.
참고문헌 (19)
- Kutzing MK, "Altered uric acid levels and disease states", J Pharmacol Exp Ther, 324, pp.1~7 (2008)
- Sautin YY, "Uric acid : the oxidant-antioxidant paradox", Nucleosides Nucleotides Nucleic Acids, 27, pp.608~619 (2008)
- Kuo CF, "Significance of serum uric acid levels on the risk of all-cause and cardiovascular mortality", Rheumatology(Oxford), 52, pp.127~134 (2013)
- Boffetta P, "A prospective study of gout and cancer", Eur J Cancer Prev, 18, pp.127~132 (2009)
- Chen CJ, "Gout patients have an increased risk of developing most cancers, especially urological cancers", Scand J Rheumatol, 43, pp.385~390 (2014)
- Kuo CF, "Increased risk of cancer among gout patients : a nationwide population study", Joint Bone Spine, 79, pp.375~378 (2012)
- Richette P, "2016 Updated EULAR evidence-based recommendations for the management of gout", Ann Rheum Dis, 76, pp.29~42 (2017)
- Tu H, "Cancer risk associated with chronic diseases and disease markers : prospective cohort study", BMJ, 360, pp.k134~ (2018)
- Chuang JP, "Association of gout and colorectal cancer in Taiwan: a nationwide population-based cohort study", BMJ Open, 9, pp.e028892~ (2019)
- Wang W, "Increased risk of cancer in relation to gout : a review of three prospective cohort studies with 50, 358 subjects", Mediators Inflamm, 2015, pp.680853~ (2015)
- Shih HJ, "Long-term allopurinol use decreases the risk of prostate cancer in patients with gout : a population-based study", Prostate Cancer Prostatic Dis, 20, pp.328~333 (2017)
- Battelli MG, "Xanthine oxidoreductase in cancer : more than a differentiation marker", Cancer Med, 5, pp.546~557 (2016)
- Strasak AM, "The role of serum uric acid as an antioxidant protecting against cancer : prospective study in more than 28000 older Austrian women", Ann Oncol, 18, pp.1893~1897 (2007)
- Strasak AM, "Serum uric acid and risk of cancer mortality in a large prospective male cohort", Cancer Causes Control, 18, pp.1021~1029 (2007)
- Xie Y, "Hyperuricemia and gout are associated with cancer incidence and mortality : a meta-analysis based on cohort studies", J Cell Physiol, 234, pp.14364~14376 (2019)
- Jee SH, "Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men", Eur J Cardiovasc Prev Rehabil, 11, pp.185~191 (2004)
- Strasak AM, "Use of penalized splines in extended Cox-type additive hazard regression to flexibly estimate the effect of time-varying serum uric acid on risk of cancer incidence : a prospective, population-based study in 78, 850 men", Ann Epidemiol, 19, pp.15~24 (2009)
- Fini MA, "Contribution of uric acid to cancer risk, recurrence, and mortality", Clin Transl Med, 1, pp.16~ (2012)
- Eisenbacher JL, "S100A4and uric acid promote mesenchymal stromal cell induction of IL-10+", IDO+ lymphocytes, 2014, pp.192, 6102~6110